Precipio Adds Another HemeScreen™ Customer
Precipio, Inc. (PRPO)
US:NASDAQ Investor Relations:
precipiodx.com/investors.html
Company Research
Source: GlobeNewswire
NEW HAVEN, Conn., June 09, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Cancer and Hematology Centers of Western Michigan (CHCWM) has adopted Precipio’s HemeScreen technology to launch molecular testing assay for hematologic malignancies such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). As part of Precipio’s recently launched Reagent Rental program, CHCWM’s laboratory is in the process of validating the HemeScreen MPN assay and will be performing it as a lab developed test (LDT) within their laboratory. Based on current volume within CHCWM’s laboratory, and taking into consideration the future add-on HemeScreen proprietary assays, Precipio anticipates potential revenues starting at $75,000 annually and possibly more than doubling as more HemeScreen products are launched in the latter half of 2020. Furthermore, we estimate that in the US there are likely over 150 similar-size potential customers wh
Show less
Read more
Impact Snapshot
Event Time:
PRPO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRPO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRPO alerts
High impacting Precipio, Inc. news events
Weekly update
A roundup of the hottest topics
PRPO
News
- Precipio Announces Year end 2023 Shareholder Update CallGlobeNewswire
- Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY [Yahoo! Finance]Yahoo! Finance
- Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoYGlobeNewswire
- Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for CancerGlobeNewswire
PRPO
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- PRPO's page on the SEC website